Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.69 |
| ▸ | PNMT | P11086 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28906763 | 0.82 | DPP4 (0.47) | DPP4PNMTADRA2CPDCD1CD274 | |
| SCHEMBL29872374 | 0.82 | DPP4 (1.00) | DPP4PNMTKMT2AHTR7PDCD1 | |
| SCHEMBL469051 | 0.82 | DPP4 (1.00) | DPP4PNMTKMT2AHTR7PDCD1 | |
| SCHEMBL744382 | 0.81 | PDCD1 (0.47) | DPP4KMT2APDCD1CD274ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4776720 | 0.80 | DPP4 (0.95) | DPP4PNMTNOS3NOS1NOS2 | |
| SCHEMBL533409 | 0.79 | DPP4 (0.42) | DPP4KMT2APDCD1CD274FOLH1 | |
| SCHEMBL25398438 | 0.79 | DPP4 (0.62) | DPP4PNMTNOS3NOS1NOS2 | |
| SCHEMBL2981250 | 0.78 | DPP4 (0.91) | DPP4PNMTNOS3NOS1NOS2 | |
| SCHEMBL8056686 | 0.78 | DPP4 (0.52) | DPP4PNMTNOS3NOS1NOS2 | |
| SCHEMBL8146098 | 0.78 | DPP4 (0.41) | DPP4ADRA2CKMT2ACYP2C19PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1373755-A | Azacycloalkanone serine protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-10-09 | — | — | CN | claimed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-103214414-B | The diamine derivative of opticity and manufacture method thereof | SANKYO CO. (JP) | 2016-02-17 | — | — | CN | disclosed |
| CN-105061509-A | Ligands and catalyst systems thereof for the catalytic oligomerization of olefinic monomers | SHELL INT RESEARCH | 2015-11-18 | — | — | CN | disclosed |
| CN-103214414-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-101263110-B | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| CN-1527849-A | Supported olefin polymerization catalysts | ��Ļ���Ű˾ | 2004-09-08 | — | — | CN | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| CN-1373755-A | Azacycloalkanone serine protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-10-09 | — | — | CN | disclosed |
| CN-1268117-A | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | DU PONT PHARM CO (US) | 2000-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | DPP4 3147/4885PNMT 3340/4885NOS3 225/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | DPP4 3147/4885PNMT 3340/4885NOS3 225/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | DPP4 3147/4885PNMT 3340/4885NOS3 225/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | DPP4 113/4885PNMT 1792/4885NOS3 939/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | DPP4 3574/4885PNMT 3441/4885NOS3 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.